Exhaled Breath Isoprene Rises During Hypoglycemia in Type 1 Diabetes by Neupane, Sankalpa et al.
TITLE: Exhaled Breath Isoprene rises during Hypoglycemia in Type 1 Diabetes 
 
RUNNING TITLE: Breath Isoprene and Hypoglycemia 
 
AUTHORS:  
Sankalpa Neupane MB BS1 
Robert Peverall PhD 2,3  
Graham Richmond PhD 2  
Tom PJ Blaikie MChem2 
David Taylor MChem2 
Gus Hancock PhD 2,3 
Mark L. Evans MD1 
 
1. Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, 
IMS-MRL, Box 289 Addenbrookes Hospital, Cambridge, UK 
2. Oxford Medical Diagnostics Ltd, Centre for Innovation and Enterprise 
Begbroke Science Park, Begbroke Hill, Begbroke OX5 1PF UK 
3. Department of Chemistry, Physical and Theoretical Chemistry Laboratory, 
University of Oxford, South Parks Road, Oxford OX1 3QZ UK 
 
  
Correspondance to  
Dr Mark Evans 
University of Cambridge,  
Wellcome Trust-MRC Institute of Metabolic Science  
IMS Metabolic Research Laboratories,  
Box 289 Addenbrookes Hospital,  
Cambridge, UK CB2 0QQ 
Mle24@cam.ac.uk 
Tel +44 (0)1223 336994 
 
Word count: 491 
Figures: 1  
 Hypoglycemia is a major fear for many with type 1 diabetes (T1D), limiting ability to 
lower glycemia. Given anecdotal reports of domestic pets alerting owners of blood 
glucose changes, especially hypoglycemia (1), we hypothesized that volatile organic 
compounds (VOCs) in exhaled breath might change at low glucose.  
We studied 8 female non-smoking participants with type 1 diabetes (T1D, age 46±5 
years, diabetes duration 23±7 years, none treated with statins) twice using a single 
blinded, computer-code randomized cross over design. An independent research 
ethics committee approved studies in advance and subjects provided written 
consent. Using a stepped insulin clamp (actrapid, NovoNordisk, Crawley UK; 0.3 
mU/kg/min increasing to1.5 mU/kg/min), on one occasion, arterialized plasma 
glucose (Yellow Springs Instrument 2300 STAT Plus™ Analyzer) was raised 
sequentially (7.1+0.8, 8.7+0.4, 10.7+0.1 mmol/l) then lowered with higher insulin 
infusion to 4.3+0.3 and 2.8+0.1 mmol/l. On control days (CON), procedures were 
identical, except that plasma glucose was maintained at 6.2+0.1 mmol/l (Figure 1A). 
For breath collection, subjects held their breath for 3 seconds, partially exhaled then 
breathed into a 1.1 litre breath bag (Fischer Analysen Instrumente GmbH). VOCs 
were measured by soft-ionisation mass spectrometry (V&F Airsense Compact Ion-
Molecule-Reaction Mass Spectrometer) by a researcher blinded to clamp glucose 
values (2). VOC values were adjusted to 5% exhaled CO2. To look specifically for a 
biomarker of low blood glucose, we compared VOC values (2-sample t test; SPSS 
Statistics 21) during hypoglycemia (2.8 mmol/l step) with values from non-
hypoglycemia. We also examined the correlation between plasma glucose and 
VOCs (STEP – CON values) across the range of experimental glucose values 
(Spearman correlation). Data are presented as mean + SEM. 
Plasma insulin (Diasorin Liaison XL chemiluminescence immunoassay) was similar 
on study days (275+109 vs 268+95 and 1001+194 vs 978+171 pmol/l; STEP vs EU 
120 and 220 min respectively). Strikingly, exhaled breath isoprene rose significantly 
at hypoglycemia (220 minute values) compared to non-hypoglycemia (Figure 1). 
Outside hypoglycemia, there was no correlation between exhaled isoprene and 
plasma glucose across the broader range of experimental plasma glucose values 
and no significant associations with other measured VOCs (acetone, methyl nitrate, 
ethanol, ethyl benzene and propane).  
It is unclear how hypoglycemia could increase isoprene. Despite being one of the 
commonest VOCs in human breath, the source of endogenous isoprene remains 
undetermined. At least in part, isoprene may be a by-product of cholesterol 
biosynthesis (3). Although glucose can alter fatty acid formation via carbohydrate 
response element binding protein (CHrEBP), this has not been described for 
cholesterol biosynthesis. (4).  Alternatively/ additionally, during hypoglycemia, 
tachycardia and increased blood flow could increase pulmonary delivery of isoprene. 
Against this, we saw no changes in other VOCs. Of note, a previous study using 
insulin clamps in T1D reported that clusters of VOCs rather than an individual VOC 
correlated with plasma glucose, although hypoglycemia was not examined (5).  
In summary, our data suggest that breath VOCs such as isoprene offer a non-
invasive alternative for monitoring changes in blood glucose in diabetes, including 
detection of hypoglycemia. 
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FIGURE LEGEND 
Exhaled breath isoprene during studies. * p < 0.01 compared to non-hypoglycemia 
 
 
 
